Φαρμακολογία-Βιοτεχνολογία
Ενότητα συζήτησης για ότιδήποτε μπορεί να ενεργήσει στον ανθρώπινο οργανισμό.Από βιταμίνες και καλλυντικά μέχρι τα συγχρονα βιοτεχνολογικά φάρμακα
Μελέτη που έγινε σε Γαλλικό Πανεπιστήμιο έδειξε ότι το Actos αυξάνει την πιθανότητα εμφάνισης καρκίνου της ουροδόχου κύστης, οδηγώντας τους Εθνικούς Οργανισμούς φαρμάκων Γαλλίας και Γερμανίας να εκδώσουν οδηγία προς το γιατρούς να σταματήσουν την συνταγογράφηση του εν λόγω φαρμάκου. Στην ίδια οδηγία συνιστάται και η διακοπή της συνταγοράφησης του Competeactπου περιέχει και αυτό πιογλιταζόνη.
Για οποιαδήποτε
<a href="http://www6.shoutmix.com/?livemedia">View shoutbox</a>
http://www.medscape.com/features/slideshow/year-in-medicine
Y.Γ mypharm: H μάχη συνεχίζεται , ο ΦΣΑ παλεύει ,ο ΠΦΣ παλεύει αλλά εμείς δεν ξεχνάμε τη δουλειά μας και αυτή δεν είναι άλλη από την επιστήμη.Χρόνια πολλά και πάλι
October 20, 2010 — Prescribing information for gonadotropin-releasing hormone (GnRH) agonists, which are a class of drugs primarily used to treat prostate cancer, will now bear a warning about the potential risk for heart disease and diabetes in men treated with these medications, the US Food and Drug Administration (FDA) announced today.
In May, the FDA announced that a preliminary and ongoing analysis had found that patients receiving GnRH agonists were at a "small increased risk" for diabetes, heart attack, stroke, and sudden death. The revised labels will include cautions in the warnings and precautions section about these potential risks.
GnRH agnoists are marketed under a variety of brand names: Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, and Zoladex. Generic products are also available.
As a component of androgen-deprivation therapy, GnRH agonists suppress the production of androgens that can stimulate the growth of prostate cancers.
The FDA's notification to manufacturers about the GnRH agonists is based on the agency's review of several published studies, according to the agency.
The relationship between heart disease risk, diabetes, and androgen deprivation therapy has not been without controversy. A medical oncologist specializing in prostate cancer treatment recently defended the safety of the therapeutic approach in an interview with Medscape Medical News.
"There is no convincing evidence that hormone blockade shortens life or causes excess heart attacks if weight gain is attended to and blood sugar levels are kept in check," said Mark Scholz, MD, from the Prostate Cancer Research Institute in Los Angeles, California.
"Hormone blockade extends life in randomized trials, both disease-specific and overall survival.
Το πιο αξιολογο ειναι η αποψη στο άρθρο το οτι οι γιατροί που δε διαβαζουν αυτόνομα και στηρίζονται στην πληροφορηση απο τις εταιρίες δεν ασκούν καλή ιατρική .
(Reuters) - Doctors tend to prescribe drugs that pharmaceutical companies promote to them and patients end up paying more but not always getting the most suitable medicines, researchers reported on Wednesday.
An analysis of 58 studies in several countries found that information from drug companies influenced the decisions doctors made, and not necessarily in a positive way.
"You couldn't say that information from pharmaceutical companies benefited doctor's prescribing, which is what pharmaceutical companies claim," said Geoffrey Spurling of the University of Queensland in Brisbane, Australia, who led the study.
"Many doctors claim they are not influenced and having done the review, that is not supported. You have to say that at least some of the time, doctors are influenced," he said in a telephone interview.
Pharmacy COPD screening service launched
Tue, 19/10/2010 - 15:37
Counter assistant Claire Gisby shows local councillor Lady Patricia Newton a spirometer
Community pharmacists in Essex are screening patients for chronic obstructive pulmonary disease as part of a pilot scheme launched last Friday (15 October 2010).
The initiative has been developed by Mid Essex Primary Care Trust, Essex Local Pharmaceutical Committee and secondary care to create a new pathway for patients who may be at risk from lung disease.
Patients will undergo spirometry screening as part of the pilot and be referred to their GP if necessary.
But they will also be offered access to other appropriate services as part of the scheme, including smoking cessation, asthma clinics or patient support groups. The opportunity for a pharmacy-based medicines use review will also be available.
Ash Pandya, chief executive of Essex LPC, said: “This project is unique in that it has arisen as a result of close collaboration between the primary care trust, secondary care and the LPC, as part of a process to redesign the pathway for patients with COPD. This project is the first of a number of initiatives that will be developed as a result of this process.”
Su Stephens, commissioning manager for long-term conditions at NHS Mid Essex, said the pilot is designed to encourage people to take steps to have healthy lungs. There is a strong emphasis on prevention, she said. She added: “The aim is to identify and treat any lung conditions at an early stage.”
The pilot is being run at seven pharmacies in the district for six months before being evaluated with the possibility of it being rolled out further.
Διαβάζοντας κανείς τη σύσταση των αντιγριπικών που κυκλοφόρησαν διαπιστώνει ότι περιέχουν στελέχη του ιού της γρίπης των χοίρων. Ενδεικτικά παραθέτουμε την σύσταση του περσινού εμβολίου που ήταν η ακόλουθη:
Διαβάζοντας το αρθρο για την υπερτροφία που προκαλείται στους νευρωνες απο τη χρηση των ορμονών των αντισυλληπτικών χαπιών είχα την εξής απορία:Γιατί να μη χρησιμοποιήσουμε την παρενέργεια των φαρμάκων αυτών για να ενισχύσουμε τους νευρωνες που εκφυλίζονται στην περίπτωση π.χ του alzheimer,parkinson κτλ?
It seems that weekly we hear about some professional athlete who sullies himself and his sport through abuse of steroids. The melodrama unfolds, careers and statistics are brought low and asterisked, and everyone bemoans another fallen competitor. Yet there are millions of cases of steroid use that occur daily with barely a second thought: Millions of women take birth control pills, blithely unaware that their effects may be subtly seeping into and modulating brain structure and activity.
It is a huge experiment whose resolution will not be known for a while, but a new study in the journal Brain Research demonstrates that the effects are likely to be dramatic. It found that birth control pills have structural effects on regions of the brain that govern higher-order cognitive activities, suggesting that a woman on birth control pills may literally not be herself -- or is herself, on steroids.
